Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

被引:111
作者
Veytsman, Irina
Nieman, Lynnette
Fojo, Tito [1 ]
机构
[1] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
ADRENAL-CORTICAL CARCINOMA; PHASE-II TRIAL; POSITRON-EMISSION-TOMOGRAPHY; INDEPENDENT PROSTATE-CANCER; CLINICAL-PRACTICE GUIDELINE; SOUTHWEST-ONCOLOGY-GROUP; HIGH-DOSE KETOCONAZOLE; CUSHINGS-SYNDROME; ADJUVANT MITOTANE; PRIMARY ALDOSTERONISM;
D O I
10.1200/JCO.2008.17.2775
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Adrenal cortical carcinoma (ACC) is a rare malignancy in which patients have poor overall 5-year survival. Patients with ACC can present with symptoms of hormone excess, including Cushing's syndrome, virilization, feminization, or-less frequently-hypertension with hypokalemia. In many patients with ACC, advanced disease at presentation precludes surgery or is followed by local relapse or distant metastatic disease that cannot be managed surgically. In these instances, chemotherapy is often tried, but its limited efficacy all too often leaves the problem of persistent hormonal excess. Physicians who treat patients with ACC and severe hypercortisolism should recognize that uncontrolled hormone production is a malignant disease, which has severe consequences that require aggressive management. Because chemotherapy benefits only a small percentage of patients, steroidogenesis inhibitors, including mitotane, ketoconazole, metyrapone, and etomidate, should be used singly or in combination even as chemotherapy is administered. Diligent management with frequent adjustments is required, especially in patients with chemotherapy-refractory tumors that continue to grow. In the absence of randomized, controlled trials, adjuvant use of mitotane remains controversial, although the authors of a recent case-control study argue for its use. Despite difficulty administering effective doses, most clinicians agree that mitotane should be used if the tumor cannot be removed surgically or should be used as adjuvant therapy if there is a high likelihood of recurrence. The option of long-term monotherapy is restricted to patients who tolerate mitotane and either experience a clinical response or are at high risk for recurrence. Recommendations are provided to help manage patients with this difficult disease and to improve the quality of their lives. J Clin Oncol 27: 4619-4629. (C) 2009 by American Society of Clinical Oncology
引用
收藏
页码:4619 / 4629
页数:11
相关论文
共 129 条
[1]
AABO K, 1987, LANCET, V2, P637
[2]
Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients [J].
Abiven, Gwenaelle ;
Coste, Joel ;
Groussin, Lionel ;
Anract, Philippe ;
Tissier, Frederique ;
Legmann, Paul ;
Dousset, Bertrand ;
Bertagna, Xavier ;
Bertherat, Jerome .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2650-2655
[3]
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma - Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a p-glycoprotein antagonist [J].
Abraham, J ;
Bakke, S ;
Rutt, A ;
Meadows, B ;
Merino, M ;
Alexander, R ;
Schrump, D ;
Bartlett, D ;
Choyke, P ;
Robey, R ;
Hung, E ;
Steinberg, SM ;
Bates, S ;
Fojo, T .
CANCER, 2002, 94 (09) :2333-2343
[4]
Whole-body positron emission tomographic scanning in patients with adrenal cortical carcinoma comparison with conventional imaging procedures [J].
Ahmed, M ;
Al-Sugair, A ;
Alarifi, A ;
Almahfouz, A ;
Al-Sobhi, S .
CLINICAL NUCLEAR MEDICINE, 2003, 28 (06) :494-497
[5]
NONHYPNOTIC LOW-DOSE ETOMIDATE FOR RAPID CORRECTION OF HYPERCORTISOLEMIA IN CUSHINGS-SYNDROME [J].
ALLOLIO, B ;
SCHULTE, HM ;
KAULEN, D ;
REINCKE, M ;
JAURSCHHANCKE, C ;
WINKELMANN, W .
KLINISCHE WOCHENSCHRIFT, 1988, 66 (08) :361-364
[6]
EFFECT OF A SINGLE BOLUS OF ETOMIDATE UPON 8 MAJOR CORTICOSTEROID HORMONES AND PLASMA ACTH [J].
ALLOLIO, B ;
DORR, H ;
STUTTMANN, R ;
KNORR, D ;
ENGELHARDT, D ;
WINKELMANN, W .
CLINICAL ENDOCRINOLOGY, 1985, 22 (03) :281-286
[7]
Prognostic parameters of metastatic adrenocortical carcinoma [J].
Assie, Guillaume ;
Antoni, Guillemette ;
Tissier, Frederique ;
Caillou, Bernard ;
Abiven, Gwenaelle ;
Gicquel, Christine ;
Leboulleux, Sophie ;
Travagli, Jean-Paul ;
Dromain, Clarisse ;
Bertagna, Xavier ;
Bertherat, Jerome ;
Schlumberger, Martin ;
Baudin, Eric .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (01) :148-154
[8]
Weiss system revisited - A clinicopathologic and immunohistochemical study of 49 adrenocortical tumors [J].
Aubert, S ;
Wacrenier, A ;
Leroy, X ;
Devos, P ;
Carnaille, B ;
Proye, C ;
Wemeau, JL ;
Lecomte-Houcke, M ;
Leteurtre, E .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (12) :1612-1619
[9]
Barzon L, 1997, ONCOLOGY, V54, P490
[10]
Baudin E, 2001, CANCER, V92, P1385, DOI 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO